

Table S1 Clinical characteristics of 440 patients with follow-up

Characteristic	Total (n=440)	Uncommon (n=37)	Common (n=403)	P
Age, years				0.058
Median [range]	61 [30–89]	61 [30–89]	57 [37–79]	
≥60, n (%)	225 (51.1)	13 (35.1)	212 (52.6)	
<60, n (%)	215 (48.9)	24 (64.9)	191 (47.4)	
Sex, n (%)				0.73
Female	265 (60.2)	21 (56.8)	244 (60.5)	
Male	175 (39.8)	16 (43.2)	159 (39.5)	
Smoking, n (%)				0.71
Yes	130 (70.5)	12 (32.4)	118 (29.3)	
No	310 (29.5)	25 (67.6)	285 (70.7)	
ECOG PS, n (%)				0.71
<2	417 (94.8)	36 (97.3)	381 (94.5)	
≥2	23 (5.2)	1 (2.7)	22 (5.5)	
Stage, n (%)				0.72
IIIA	155 (35.2)	14 (37.8)	141 (35.0)	
IIIB	285 (64.8)	23 (62.2)	262 (65.0)	
PET-CT, n (%)				0.13
Yes	126 (28.6)	15 (40.5)	111 (27.5)	
No	314 (71.4)	22 (59.5)	292 (72.5)	
Treatment, n (%)				0.37
RT + <i>EGFR</i> -TKIs	104 (23.6)	9 (23.4)	96 (23.8)	
<i>EGFR</i> -TKIs	231 (52.5)	16 (43.2)	215 (53.3)	
CRT	105 (23.7)	12 (32.4)	95 (22.8)	

CRT, chemoradiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; *EGFR*, epidermal growth factor receptor; PET-CT, positron emission tomography-computed tomography; RT, radiotherapy; TKIs, tyrosine kinase inhibitors.

Table S2 Clinical characteristics of patients with uncommon mutation

Characteristic	Total (n=49)	Compound (n=17)	Single (n=32)	P
Age, years				0.56
Median [range]	57 [37–80]	58 [37–79]	57 [39–80]	
≥60	20 (40.8)	8 (47.1)	12 (37.5)	
<60	29 (59.2)	9 (52.9)	20 (62.5)	
Sex, n (%)				0.77
Female	28 (57.1)	9 (52.9)	19 (59.4)	
Male	21 (42.9)	8 (47.1)	13 (40.6)	
Smoking, n (%)				0.53
Yes	15 (30.6)	4 (23.5)	11 (34.4)	
No	34 (69.4)	13 (76.5)	21 (65.6)	
ECOG PS, n (%)				>0.99
<2	47 (95.9)	16 (94.1)	31 (96.9)	
≥2	2 (4.1)	1 (5.9)	1 (3.1)	
Stage, n (%)				0.75
IIIA	15 (30.6)	6 (35.3)	9 (28.1)	
IIIB	24 (69.4)	11 (64.7)	23 (71.9)	
PET-CT, n (%)				0.36
Yes	18 (36.7)	8 (47.1)	10 (31.3)	
No	31 (63.3)	9 (52.9)	22 (68.8)	

ECOG PS, Eastern Cooperative Oncology Group performance status; PET-CT, positron emission tomography-computed tomography.

Table S3 Clinical characteristics of patients with uncommon mutation

Characteristic	Total (n=37)	Compound (n=15)	Single (n=22)	P
Age, years				0.30
Median [range]	57 [37–80]	58 [37–79]	56 [39–72]	
≥60, n (%)	13 (35.1)	7 (46.7)	6 (27.3)	
<60, n (%)	24 (64.9)	8 (53.3)	16 (72.7)	
Sex, n (%)				P>0.99
Female	21 (56.8)	9 (50.0)	12 (54.5)	
Male	16 (43.2)	6 (40.0)	10 (45.5)	
Smoking, n (%)				0.72
Yes	12 (32.4)	4 (26.7)	8 (36.4)	
No	25 (67.6)	13 (73.3)	14 (63.6)	
ECOG PS, n (%)				0.41
<2	36 (97.3)	14 (93.3)	22 (100.0)	
≥2	1 (6.7)	1 (6.7)	0	
Stage, n (%)				P>0.99
IIIA	14 (37.8)	6 (40.0)	8 (36.4)	
IIIB	23 (62.2)	9 (60.0)	14 (63.6)	
PET-CT, n (%)				0.31
Yes	15 (40.5)	8 (53.3)	7 (31.8)	
No	22 (59.5)	7 (46.7)	15 (68.2)	
Treatment, n (%)				0.12
RT + TKIs	9 (24.3)	5 (33.3)	4 (18.2)	
EGFR-TKIs	16 (43.2)	8 (53.3)	8 (36.4)	
CRT	12 (32.4)	2 (33.3)	10 (45.5)	

CRT, chemoradiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; PET-CT, positron emission tomography-computed tomography; RT, radiotherapy; TKIs, tyrosine kinase inhibitors.

Table S4 Recurrence patterns according to EGFR uncommon mutation

First site of progression	Total, n (%)	Compound, n (%)	Single, n (%)	P
All	34 (91.9)	15 (100.0)	19 (86.4)	0.26
Distant only	10 (29.4)	3 (20.0)	7 (31.8)	0.48
Loco-regional only	15 (44.1)	9 (60.0)	6 (27.3)	0.09
Distant + loco-regional	9 (24.3)	3 (20.0)	6 (27.0)	0.71
Brain	9 (24.3)	3 (20.0)	6 (27.3)	0.71

EGFR, epidermal growth factor receptor.